Maine Clinical Trials Report — May 2026

For individuals in Maine considering participation in clinical research, May 2026 brings a focused set of opportunities, particularly for those who can act quickly. Out of the 199 clinical trials currently recruiting across the state, a total of 6 are slated to conclude enrollment within the next 90 days. This includes a valuable opportunity for healthy volunteers, with 1 of these rapidly closing studies actively seeking participants without specific health conditions. Exploring these options promptly is advisable before they are no longer available, representing a chance to contribute to medical advancements in a timely manner.

Patients managing certain health conditions also have limited time to join specific research initiatives. Trials addressing various forms of cancer, chronic conditions, and gastrointestinal issues are among those with impending enrollment deadlines. The conditions with trials closing soon include:

• Stage IV lung cancer AJCC v8 and Advanced lung non-small cell carcinoma: These trials are crucial for patients with advanced forms of lung cancer, offering potential new treatment avenues.
• Recurrent lung non-small cell carcinoma: Focuses on individuals whose lung cancer has returned, seeking improved outcomes.
• Metastatic small intestinal adenocarcinoma and Stage III small intestinal adenocarcinoma AJCC v8: These studies target specific, often aggressive, cancers of the small intestine.
• Irritable bowel syndrome with constipation (IBS-C): A common gastrointestinal disorder, research here aims to improve quality of life for those affected.
• Chronic granulomatous disease (CGD): A rare genetic disorder affecting the immune system, these trials are vital for advancing understanding and treatment.
• Chronic illness and related areas like Advance directives and Communication: These broader studies often explore ways to improve care, patient experience, and end-of-life planning for individuals with long-term health challenges.

A Major New Research Initiative from Novo Nordisk A/S

This month, Maine welcomes a significant new Phase 3 drug trial sponsored by Novo Nordisk A/S, a global leader in pharmaceutical research known for its work in diabetes and obesity. This study represents a notable opportunity for individuals living with specific heart conditions and obesity to contribute to a large-scale research effort, potentially impacting future treatment standards.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of an investigational drug, NNC0487-0111. The study focuses on individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) who also have excess body weight. HFpEF and HFmrEF are types of heart failure where the heart muscle still pumps blood, but not as effectively as it should, often leading to symptoms like shortness of breath and fatigue. Comparing the investigational drug's performance against a placebo is a critical step in understanding potential new treatments for these complex, often debilitating conditions, offering hope for improved patient outcomes.

This new trial is the only one to open in Maine this month, maintaining a consistent pace of new research initiatives. Over the past six months, the state has seen a steady introduction of new trials, with 1 new trial opening in December 2025, 2 in January 2026, 1 in March, 1 in April, and now 1 in May. This consistent, albeit focused, introduction of new studies ensures ongoing opportunities for participation in cutting-edge research.

Expanding Participation: Healthy Volunteers and Demographics

While the single new trial this month focuses on specific patient populations, Maine continues to offer valuable avenues for healthy volunteers to contribute to scientific discovery. Currently, a total of 11 clinical trials across the state are actively recruiting healthy individuals. These studies are crucial for establishing baseline data, understanding disease progression, and testing new interventions, providing a chance for those without specific health conditions to play a vital role in medical advancements. As mentioned, 1 of these healthy volunteer opportunities is among the trials closing soon, emphasizing the need for prompt action for interested individuals.

Regarding broader eligibility, the new trial launched this month is open to older adults, ensuring that senior populations have ample opportunity to contribute to medical science. No new trials this month are exclusively for children, females, or males. Across all currently recruiting trials in Maine, a diverse range of eligibility criteria ensures that many individuals can find a suitable study, reflecting the varied health needs and research interests within the state.

Maine's Research Landscape: Geographic Reach and Accessibility

Maine's clinical research efforts are spread across the state, ensuring accessibility for residents in various regions. Currently, a robust total of 199 clinical trials are actively recruiting participants across 28 cities and at 109 distinct research sites. This broad distribution means that research opportunities are not confined to a single metropolitan area but are available throughout Maine, from its coastal communities to its inland towns.

This month's new trial, sponsored by Novo Nordisk A/S, is located in Scarborough. While this particular study is situated in one specific city, the overall landscape of clinical research in Maine offers options in numerous communities. This widespread presence allows more residents to consider participating in studies without extensive travel, making it easier to engage with important medical research close to home.

As we move further into 2026, Maine's clinical research community will continue to focus on advancing medical knowledge through both ongoing and new studies. Individuals interested in contributing to these efforts, whether as patients seeking new treatments or healthy volunteers supporting scientific understanding, are encouraged to explore the available options and consider the profound impact of their participation on future healthcare.